- Home
- ALLT vs DRUG Comparison
ALLT vs DRUG Comparison
Compare ALLT & DRUG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALLT
- DRUG
- Stock Information
- Founded
- ALLT 1996
- DRUG 2019
- Country
- ALLT Israel
- DRUG United States
- Employees
- ALLT N/A
- DRUG N/A
- Industry
- ALLT Telecommunications Equipment
- DRUG Pharmaceuticals and Biotechnology
- Sector
- ALLT Telecommunications
- DRUG Health Care
- Exchange
- ALLT Nasdaq
- DRUG Nasdaq
- Market Cap
- ALLT 458.2M
- DRUG 433.7M
- IPO Year
- ALLT 2006
- DRUG N/A
- Fundamental
- Price
- ALLT $9.44
- DRUG $51.46
- Analyst Decision
- ALLT Strong Buy
- DRUG Strong Buy
- Analyst Count
- ALLT 3
- DRUG 9
- Target Price
- ALLT $12.75
- DRUG $81.67
- AVG Volume (30 Days)
- ALLT 340.7K
- DRUG 147.8K
- Earning Date
- ALLT 11-20-2025
- DRUG 08-11-2025
- Dividend Yield
- ALLT N/A
- DRUG N/A
- EPS Growth
- ALLT N/A
- DRUG N/A
- EPS
- ALLT N/A
- DRUG N/A
- Revenue
- ALLT $95,342,000.00
- DRUG N/A
- Revenue This Year
- ALLT $10.42
- DRUG N/A
- Revenue Next Year
- ALLT $13.06
- DRUG N/A
- P/E Ratio
- ALLT N/A
- DRUG N/A
- Revenue Growth
- ALLT 4.74
- DRUG N/A
- 52 Week Low
- ALLT $3.35
- DRUG $23.18
- 52 Week High
- ALLT $11.42
- DRUG $70.23
- Technical
- Relative Strength Index (RSI)
- ALLT 44.13
- DRUG 40.36
- Support Level
- ALLT $9.54
- DRUG $52.04
- Resistance Level
- ALLT $10.69
- DRUG $64.81
- Average True Range (ATR)
- ALLT 0.44
- DRUG 5.30
- MACD
- ALLT -0.10
- DRUG -1.94
- Stochastic Oscillator
- ALLT 17.65
- DRUG 2.21
About ALLT Allot Ltd.
Allot Ltd is a provider of network intelligence and security solutions for service providers and enterprises. The company's solutions are deployed globally for network and application analytics, traffic control and shaping, and network-based security services. The firm's multi-service platforms are deployed by mobile, fixed, and cloud service providers and enterprises. The company has a customer base in Europe, Asia and Oceania, the Americas, the Middle East, and Africa.
About DRUG Bright Minds Biosciences Inc.
Bright Minds Biosciences Inc is focused on developing novel transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult to treat disorders such as resistant epilepsy, treatment resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.